Evaluation of efficacy and safety of Fenofibrate in COVID-19 patients
Phase 3
- Conditions
- COVID-19.COVID-19U07.1
- Registration Number
- IRCT20220612055149N1
- Lead Sponsor
- Artesh University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Age more than 18 years
Confirmed diagnosis of COVID-19 with RT-PCR
Hospitalization
Symptom onset lower than 10 days
Exclusion Criteria
Pregnancy, breastfeeding
Known hypersensitivity to fibrate agents
History of Fenofibrate treatment
Previous treatment with warfarin, ciclosporin, tacrolimus, and atorvastatin more than 40 milligrams (mg) daily
History of liver diseases, and hypothyroidism
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mortality. Timepoint: From admission to 3 months after discharge. Method of measurement: Electronic records and contacting patient after discharge.;ICU admission. Timepoint: From hospitalization to discharge. Method of measurement: Patient status by electronic records.
- Secondary Outcome Measures
Name Time Method Hospitalization days. Timepoint: At discharge. Method of measurement: Patient electronic records.;ICU stay. Timepoint: At dischagre. Method of measurement: Patient electronic records.;Mechanical ventilaton. Timepoint: At discharge. Method of measurement: Need for mechanical ventilation by reviewing electronic records.